CXCL8 (2, 20, and 200 pg/ml) and CCL20 (5, 50, and 500 pg/ml) enhanced Ki-67 gene expression, but only 200 pg/ml of CXCL8 and 500 pg/ml of CCL20 enhanced early osteogenic marker ge... by Janak L. Pathak (759122)

Decrease of Paneth cells in mice fed a high-fat diet (HFD). by June-Chul Lee (2850536)

<i>Cin85</i>-Deficiency results in defective clearance of LCMV-c13 and is correlated with decreased neutralizing antibody titer. by Saravanan Raju (5181014)

Administration of γPGA attenuates Th2 immune responses elicited by the cysteine protease papain through a decrease in basophils. by Hyun Jung Park (116737)

V3Nter decreases colony formation and induces tumor cell death in HCT116 and HepG2 cells. by Delphine Quélard (43727)

Deletion of <i>sagA</i> alone results in a decrease in nasopharyngeal infection. by Blake A. Shannon (14197601)

Decreased numbers of motor neurons in Tc1 and Dp(16)1Yey mice. by Sheona Watson-Scales (586942)

Knockdown of NRP1 increases while knockdown of NRP2 decreases formation of Schwann cell clusters. by Kasper C. D. Roet (444802)

“…<p>(A–C) Representative SC clusters when co-cultured with MCs for 5 days after a transfection with siGlo, siNRP1 pool or siNRP2 pool respectively. …”

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects: